H.C. Wainwright still ‘optimistic’ on Phase 2 data for AnaptysBio’s rosnilimab
PremiumThe FlyH.C. Wainwright still ‘optimistic’ on Phase 2 data for AnaptysBio’s rosnilimab
11d ago
AnaptysBio weakness on competitor news a buying opportunity, says Guggenheim
Premium
The Fly
AnaptysBio weakness on competitor news a buying opportunity, says Guggenheim
11d ago
AnaptysBio to be weak on Lilly pulling peresolimab from pipeline, says Stifel
Premium
The Fly
AnaptysBio to be weak on Lilly pulling peresolimab from pipeline, says Stifel
11d ago
AnaptysBio price target raised to $30 from $20 at Truist
PremiumThe FlyAnaptysBio price target raised to $30 from $20 at Truist
3M ago
AnaptysBio to sell 2.75M shares at $36.50 in registered direct offering
Premium
The Fly
AnaptysBio to sell 2.75M shares at $36.50 in registered direct offering
3M ago
AnaptysBio price target raised to $42 from $34 at Wedbush
Premium
The Fly
AnaptysBio price target raised to $42 from $34 at Wedbush
3M ago
Arm and Accenture upgraded: Wall Street’s top analyst calls
PremiumThe FlyArm and Accenture upgraded: Wall Street’s top analyst calls
4M ago
AnaptysBio upgraded to Overweight from Neutral at JPMorgan
Premium
The Fly
AnaptysBio upgraded to Overweight from Neutral at JPMorgan
4M ago
Anaptys participates in a conference call with JPMorgan
Premium
The Fly
Anaptys participates in a conference call with JPMorgan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100